On June 5, 2025, the U.S. Food & Drug Administration (FDA) granted De Novo authorization to Clairity Breast, the first-ever AI-powered platform that predicts a woman’s risk of developing breast cancer over the next five years—using only a standard mammogram. De Novo authorization is especially meaningful as it marks the very first platform of its kind.